Abstract
This case presents a patient with hypertrophic osteoarthropathy of the lower extremities that developed secondary to congenital cyanotic heart disease. The major clinical manifestation was severe bilateral leg pain. The pain that was debilitating in nature completely resolved following a single administration of 60 mg pamidronate. Hypertrophic osteoarthropathy (HOA) is an acquired, uncommon disorder of obscure etiology. It has been described mainly in association with chronic suppurative pulmonary diseases, bronchogenic carcinoma and lung metastases, cystic fibrosis, and cyanotic congenital malformations of the heart.
Similar content being viewed by others
References
Semple T, McCluskie RA (1955) Generalized hypertrophic osteoarthropathy in association with bronchial carcinoma. Br Med J 1:754–759
Garske LA, Bell SC (2002) Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis. Chest 121:1363–1364
Martinez-Lavin M (1992) Cardiogenic hypertrophic osteoarthropathy. Clin Exp Rheumatol 10 [Suppl 7]:19–21
Pineda C, Fonseca C, Martinez-Lavin M (1990) The spectrum of soft tissue and skeletal abnormalities of hypertrophic osteoarthropathy. J Rheumatol 17:626–632
Reid IR (2003) Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 15:458–463
Suzuma T, Sakurai T, Yoshimura G, Umemura T, Tamaki T, Yoshimasu T, Naito (2001) Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. Anticancer Drugs 12:731–734
Silveri F, De Angelis R, Argentati F, Brecciaroli D, Muti S, Cervini C (1996) Hypertrophic osteoarthropathy: endothelium and platelet function. Clin Rheumatol 15:435–439
Silveira LH, Martinez-Lavin M, Pineda C, Fonseca MC, Navarro C, Nava A (2000) Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol 18:57–62
Abe Y, Kurita S, Ohkubo Y, et al. (2002) A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor. Anticancer Res 22:3485–3488
Luckman SP, Hughes DE, Coxon FP, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589
Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S (1999) Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264:108–111
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Amital, H., Applbaum, Y.H., Vasiliev, L. et al. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol 23, 330–332 (2004). https://doi.org/10.1007/s10067-004-0941-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-004-0941-4